Fulvestrant loading, tumor markers, and ongoing trials [1]

Community Oncology

Volumn 4, Issue 11, 2007, Pages 649-650

  Kaniklidis, Constantine ^a,b  

^a Breast Cancer Watch   (United States)

^b European Association for Cancer Research (EACR)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FULVESTRANT; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL TRIAL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LETTER; LOADING DRUG DOSE; POSTMENOPAUSE; STATISTICAL SIGNIFICANCE;

EID: 36849089023     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70154-1     Document Type: Letter

References (17)

1. Gradishar WJ. Update on fulvestrant for hormone receptor-positive advanced breast cancer. Commun Oncol 2007;4:220-231.
2. Scheff RJ. Fulvestrant offers an attractive treatment option for postmenopausal breast cancer. Commun Oncol 2007;4:231-232.
3. Gradishar W, Chia S, Piccart M, on behalf of the EFECT Writing Committee. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. Paper presented at the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Tex. Abstract 12.
4. As cited in Robertson JF. Fulvestrant (Faslodex®) how to make a good drug better. Oncologist 2007;12:774-784.
5. Moussallem CD, Lopez A, Gauthier A, et al. Fulvestrant in metastatic breast cancer: standard dose vs loading dose - a retrospective study. J Clin Oncol 2006;24(18S):10575.
6. Lower EE, Esparaz BT, Garnett SA, Wade JL. Evaluation of fulvestrant in clinical practice: use of an electronic data registry. Clin Breast Cancer 2007;7:565-569.
7. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-238.
8. Dodwell D, Pippen J. Time to response: comparison of fulvestrant and oral endocrine agents. Clin Breast Cancer 2006;7:244-247.
9. th Annual San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, Tex. Abstract 5092.
10. Bartsch R, Wenzel C, Altorjai G, et al. Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. Clin Cancer Res 2007;13:4435-4439.
11. Robertson JF, Agrawal E, Gutteridge E, Cheung K, Evans, AJ. Correlation of CA15.3 levels with clinical response in advanced breast cancer (ABC) patients receiving fulvestrant. J Clin Oncol 2006;24(18S):641.
12. Sonoo H, Kurebayashi J. Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Surg Today 1996;26:250-257.
13. Loprinzi CL, Tormey DC, Rasmussen P, et al. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol 1986;4:46-56.
14. Guadagni F, Ferroni P, Carlini S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 2001;7:2357-2362.
15. Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990;65:193-199.
16. Sjöström J, Alfthan H, Joensuu H, et al. Serum tumour markers CA 15-3, TPA, TPS, hCGβ and TATI in the monitoring of chemotherapy response in metastatic breast cancer. Scand J Clin Lab Invest 2001;61:431-441.
17. Young O, Renshaw L, White S, et al. Randomized pre-operative study of 750 mg of fulvestrant and 20 mg of tamoxifen in premenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2005;94(suppl 1):S235. Abstract 5084.